2025年1月7日，未来股份公告收到证监会处罚决定书，经查明，2022年下半年，未来股份通过安排其关 联方及第三方公司充当煤炭贸易业务参与方、统一拟定煤炭业务相关合同及单据、安排煤炭贸易业务资 金划转、利用获取的物流信息和单据等伪造煤炭贸易货物流转等方式，虚构煤炭贸易业务，以此虚增收 入、利润，导致未来股份2022年第三季度报告、2022年年度报告存在虚假记载。其中，2022年第三季度 报告虚增营业收入955，764，870.80元，占当期披露营业收入的95.20%，虚增利润总额11，839， 598.84元，占当期披露利润总额绝对值的29.26%；2022年年度报告虚增营业收入110，334，012.52元， 占当期披露营业收入的66.61%，虚增利润总额110，334，012.52元，占当期披露利润总额绝对值的 837.84%。 许峰律师认为，在2022年10月29日到2023年4月25日之间买入未来股份股票，并且在2023年4月25日后卖 出或继续持有股票的投资者，还可发起索赔。（未来股份维权入口） 除了未来股份投资者索赔案提交法院立案，2025年11月20日，许峰律师代理的部分世纪华通（维权）投 资者 ...

Group 1 - The core issue involves investor claims against Shengtun Mining due to false statements leading to financial discrepancies in their reported earnings and profits [1][2] - Shengtun Mining's financial misconduct includes overstating revenue by approximately 359.37 million yuan in 2021 and 84.15 million yuan in 2022, while also underreporting revenue in 2023 by about 78.19 million yuan [1] - The law firm is actively pursuing claims for investors who purchased Shengtun Mining shares between April 26, 2022, and April 22, 2024, and either sold or held their shares post-April 22, 2024 [2][3] Group 2 - Jin Yi Culture has also faced legal action for similar financial misreporting, with the company overstating inventory by 610 million yuan in 2020 and 637 million yuan in 2021 [2] - Investors who bought Jin Yi Culture shares between April 30, 2021, and May 1, 2023, are eligible to file claims, as the case is nearing its deadline [3] - The law firm has a history of successfully representing investors in securities fraud cases, having handled nearly 200 cases with favorable outcomes [3]

Core Viewpoint - Huizhou Intelligent Technology Group Co., Ltd. has been penalized by the China Securities Regulatory Commission (CSRC) for false financial disclosures, leading to significant financial misstatements in 2019 and 2020 [2][3]. Summary by Sections Administrative Penalties - The CSRC found that Huizhou Intelligent's subsidiaries engaged in false advertising and inflated revenue, resulting in a cumulative revenue inflation of 59.90 million yuan and 96.89 million yuan for 2019 and 2020, respectively, which accounted for 5.08% and 13.42% of reported figures [2]. - The inflated profits totaled 14.16 million yuan and 17.77 million yuan for the same years, representing 0.88% and 8.72% of the reported profit [2]. Legal Implications for Investors - Investors affected by the false disclosures can seek civil compensation for losses incurred due to the company's actions, including differences in investment, commissions, stamp duties, and interest losses [3]. - A lawyer is actively recruiting investors who purchased Huizhou Intelligent's securities between April 29, 2020, and April 28, 2025, for potential claims [3]. Conditions for Claims - The conditions for claims include providing necessary documentation such as identification and trading records, and the final conditions will depend on the CSRC's administrative penalty conclusions and court rulings [4].

Group 1 - The investor compensation case against Pengdu Agriculture and Animal Husbandry has been officially filed in Changsha Intermediate Court, with ongoing efforts to accept additional claims from other investors [1] - Pengdu Agriculture and Animal Husbandry has a precedent of investors winning compensation claims due to false statements, and investors who suffered losses from such misrepresentations can still initiate claims [1] - The company was found to have failed to timely disclose the non-operating fund occupation by its controlling shareholder and had significant omissions in its annual and semi-annual reports from 2020 to 2022 [1] Group 2 - Century Huatong has also faced legal action, with a compensation case filed in Shaoxing Intermediate People's Court, and some investors have already received compensation [1] - The company received an administrative penalty from the China Securities Regulatory Commission for false records regarding goodwill in its annual reports from 2018 to 2022, including failing to conduct goodwill impairment tests [2] - Century Huatong's financial reports from 2019 to 2022 contained errors in goodwill disclosures and failed to report certain segments according to accounting standards [3]

Core Points - The article discusses the legal developments regarding investor claims against Yuan Cheng Co., Ltd. (元成股份) due to false statements made by the company [1] - It highlights the administrative penalty notice issued by the Zhejiang Regulatory Bureau of the CSRC, which clarifies the illegal activities of Yuan Cheng Co., Ltd. [1] Summary by Sections Yuan Cheng Co., Ltd. (元成股份) - Yuan Cheng Co., Ltd. has been found to have false records in its annual reports from 2020 to 2022, inflating revenue and profit figures by overstating project costs and values [1] - The company also fabricated significant false information in its 2022 non-public stock issuance documents [1] - Investors who purchased Yuan Cheng shares between April 15, 2021, and January 31, 2024, and sold or held the shares after January 31, 2024, are eligible to file claims [1] Poly United (保利联合) - Poly United received an administrative penalty notice from the Guizhou Regulatory Bureau of the CSRC, revealing that the company underreported bad debt provisions, leading to inflated net profits for the years 2019, 2020, and 2021 [2] - The specific amounts of underreported bad debt provisions were 43.12 million yuan in 2019, 77.75 million yuan in 2020, and 235.77 million yuan in 2021, with the latter causing a change in profit and loss status [2] - Investors who bought Poly United shares between April 28, 2020, and April 28, 2023, and sold or held the shares after April 28, 2023, can still initiate claims as the statute of limitations is running out [2]

Core Viewpoint - Changjiang Pharmaceutical Holdings Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which may lead to civil compensation claims from affected investors [1][2]. Summary by Relevant Sections Company Investigation - The CSRC has decided to investigate Changjiang Pharmaceutical due to allegations of false financial reporting, which violates the Securities Law of the People's Republic of China [1]. - The investigation could result in civil liability for the company, its major shareholders, and executives if investors suffer losses due to these alleged misrepresentations [1]. Investor Compensation - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased securities of Changjiang Pharmaceutical before November 7, 2025, and either sold or continued to hold them after this date [1]. - The conditions for compensation claims will be adjusted based on the conclusions of the CSRC's administrative penalties and the final court rulings regarding the legal aspects of the claims [1][2]. Legal Process and Requirements - Investors are advised that while they can file lawsuits directly, the lack of an administrative penalty decision may increase the risk of losing such cases [2]. - The progress of civil compensation lawsuits may be affected by the company's potential delisting or bankruptcy proceedings [2]. - Required materials for investors to register for compensation include a copy of their ID, original securities account information, and transaction records [2].

Core Points - Qingdao Zhongcheng (300208) has received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) for false statements in its financial reports [1][2] - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, is currently accepting claims from investors who suffered losses due to these violations [1][2] Summary by Sections Financial Misstatements - Qingdao Zhongcheng's annual reports from 2017 to 2022 contained significant false records, including: - 2017: Overstated revenue by 1,403.22 million, 92.18% of reported revenue; overstated profit by 552.77 million, 136.17% of reported profit [1] - 2018: Overstated revenue by 467.89 million, 36.00% of reported revenue; overstated profit by 217.76 million, 94.92% of reported profit [1] - 2019: Understated revenue by 672.44 million, 88.83% of reported revenue; understated profit by 285.38 million, 78.36% of reported profit [1] - 2020: Overstated intangible assets by 300.23 million, 6.53% of total assets; understated revenue by 343.08 million, 118.51% of reported revenue; understated profit by 281.80 million, 56.22% of reported profit [1] - 2021: Overstated intangible assets by 309.70 million, 7.37% of total assets; understated revenue by 0.73 million, 0.46% of reported revenue; overstated profit by 0.50 million, 5.83% of reported profit [1] - 2022: Overstated intangible assets by 309.70 million, 7.42% of total assets [1] Legal Proceedings - Investors who purchased Qingdao Zhongcheng stock between April 25, 2018, and April 29, 2024, may initiate claims for compensation [2] - The law firm is also handling claims for investors of Haofeng Technology (300419), which has also faced penalties from the CSRC for similar violations [2][3] Haofeng Technology Violations - Haofeng Technology was found to have inflated its 2020 revenue by 73.13 million, 11.43% of its annual revenue, due to misreporting related to financing activities [2][3] - Investors who bought Haofeng Technology stock between April 26, 2021, and December 27, 2023, are eligible to file claims [3]

Core Viewpoint - The case of Poly United (002037) has reached a settlement stage, with ongoing efforts to accept claims from other investors due to previous financial misconduct [1] Summary by Relevant Sections Legal Proceedings - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, is currently handling claims for investors against Poly United, with the case now in the settlement process [1] - The law firm continues to accept claims from other investors, indicating a broader scope of potential legal action [1] Financial Misconduct - The China Securities Regulatory Commission (CSRC) issued an administrative penalty against Poly United, revealing significant underreporting of bad debt provisions: - In 2019, the company underreported bad debt provisions by 43,121,976.07 yuan, resulting in an inflated net profit of 36,653,679.66 yuan, which was 19.95% of the disclosed amount [1] - In 2020, the underreported amount was 77,752,927.99 yuan, inflating net profit by 65,892,497.89 yuan, accounting for 43.24% of the disclosed amount [1] - In 2021, the company underreported bad debt provisions by 235,768,852.67 yuan, leading to an inflated net profit of 200,267,416.27 yuan, which was 124.47% of the disclosed amount, affecting the overall profit and loss for that year [1] Investor Claims - Investors who purchased Poly United shares between April 28, 2020, and April 28, 2023, and sold or held the shares after April 28, 2023, are still eligible to file claims, as the statute of limitations is running out [1]

Group 1 - The ongoing investor compensation case against Silver River Technology (银江技术) is being actively pursued, with multiple filings submitted to the court, and the legal team is accepting additional claims from other investors [1] - Silver River Technology has been found guilty of several violations, including failure to disclose non-operating fund occupation by related parties and significant omissions in financial reports from 2018 to 2023 [1] - Investors who purchased Silver River Technology shares between April 19, 2019, and April 30, 2024, and sold or held the shares after April 30, 2024, may initiate compensation claims based on the violations identified [1] Group 2 - Yangzi New Materials (扬子新材) has received an administrative penalty from the China Securities Regulatory Commission (CSRC) for significant omissions in its annual report, including undisclosed related party fund occupations [2] - The company also faced accusations of false reporting, with approximately 137 million yuan in inflated revenue reported in 2020, which constituted about 11% of the total reported revenue for that year [4] - Investors who bought Yangzi New Materials shares between April 29, 2019, and December 30, 2022, and sold or held the shares after December 30, 2022, are eligible to file compensation claims based on the identified violations [4]

Core Viewpoint - The news highlights ongoing legal actions and claims against Ningke Biological and Caesar Culture, with investors seeking compensation due to alleged misconduct and financial discrepancies by these companies [1][2][3][4]. Group 1: Ningke Biological (600165) - Ningke Biological has received a court ruling in favor of investors, allowing them to claim compensation [1]. - The company is undergoing restructuring, with a court decision to accept its reorganization plan, and the deadline for creditors to file claims has been extended to October 31, 2025 [1]. - The proposed repayment plan for ordinary creditors includes cash repayment for amounts up to 150,000 yuan, while amounts exceeding this will be compensated with trust beneficiary rights and additional shares [1]. Group 2: Caesar Culture (002425) - Caesar Culture has been penalized by the Guangdong Securities Regulatory Bureau for financial misconduct, including failing to disclose significant debts and inflating profits by 15.55% in its 2021 annual report [3][4]. - Investors who purchased Caesar Culture shares between April 27, 2022, and May 6, 2024, may also initiate claims for compensation [4]. - The company is currently facing legal scrutiny, with claims being filed against it for alleged false statements and failure to disclose major events [4].